Evidence map›Paper›PMID 42422767›Full record

ArticleMolecular therapy. Advances2026

NK cell immunotherapy after analytic treatment interruption is associated with HIV viral control.

Liliana K Thron, Pongthorn Pumtang-On, Jae-Woong Chang, Maxwell E Cantor, Ian Gorrell-Brown, Kelsie L Becklin, Zoe E Quinn, Ahmad F Karim, Aaron K Rendahl, Mary S Pampusch and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Liliana K ThronDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Pongthorn Pumtang-OnDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Jae-Woong ChangDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.
Maxwell E CantorDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Ian Gorrell-BrownDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Kelsie L BecklinDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Zoe E QuinnDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Ahmad F KarimAgile Vaccines and Therapeutics, Infectious Diseases Directorate, Naval Medical Research Command, Silver Spring, MD, USA.
Aaron K RendahlDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Mary S PampuschDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Sofia A CasaresAgile Vaccines and Therapeutics, Infectious Diseases Directorate, Naval Medical Research Command, Silver Spring, MD, USA.
Vaiva VezysCenter for Immunology, Department of Microbiology and Immunology, University of Minnesota, Minneapolis, MN 55455, USA.
Branden S MoriarityDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.
Pamela J SkinnerDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Minneapolis, MN 55455, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 39.9 million individuals are living with HIV worldwide. There is a need to develop novel therapeutics to improve treatment or cure HIV. In this study, we evaluated HIV reservoir-targeting chimeric antigen receptor (CAR)/CXCR5 natural killer (NK) cells armored with IL-15 and PD-1 knockout as well as control activated NK cells for their safety and efficacy by treating antiretroviral therapy (ART)-suppressed, HIV-infected humanized DRAGA mice following ART interruption. There were no adverse health outcomes associated with cell infusions. At 56 days post-treatment (DPT), 62.5% of CAR NK-treated and 50% of control NK-treated groups had viral loads below the detection limit compared with 0% of the saline control group. CAR NK-treated animals had, on average, 1.88 times higher peak NK cell levels than control NK-treated animals, and elevated levels of NK cells persisted up to 28 DPT in treated animals. Importantly, animals that had undetectable viral loads at 56 DPT had earlier viral rebound post-ART interruption that coincided with high levels of NK cells, suggesting that timing of treatment with viral recrudescence may play a role in efficacy. This is the first study evaluating NK cell therapies in hDRAGA mice and demonstrates the promise of NK cell therapies for curing HIV.

Indexed as

base editorCAR therapyHIVhumanized DRAGA miceNK cellsnonviral engineeringtransposon engineering

Identifiers

PMID42422767
PMCPMC13343159

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.